Pharmaceuticals

FDA approves Filspari for adult patients with IgA nephropathy

bexib
By bexib 0 Min Read

Filspari is believed to be the first non-immunosuppressant treatment to significantly slow the decline of kidney function in adults with IgA nephropathy.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Russia’s Prosecution of the War in Ukraine: Can It Square the Circle of Probable Boundary Conditions?
Next Article First survey of regional housing markets in August
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Processing superalloys while cooling them
Manufacturing
Carlowley Castle announces new venture redefining luxury hospitality, opening doors to Scotland’s luxury estates
Hospitality & Tourism
Fintech funding will “stabilize” in 2025, venture capital prioritizes AI fintech
Banking
6 amazing projects from 2024
Manufacturing